Archive · CNBC Markets
Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
ZAZTEK archives the headline, summary and publication date so the story stays findable. The full article remains the publisher's. Read it at CNBC Markets →